- Home
- JL vs BCDA Comparison
JL vs BCDA Comparison
Compare JL & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JL
- BCDA
- Stock Information
- Founded
- JL 1985
- BCDA N/A
- Country
- JL Hong Kong
- BCDA United States
- Employees
- JL N/A
- BCDA N/A
- Industry
- JL
- BCDA Biotechnology: Pharmaceutical Preparations
- Sector
- JL
- BCDA Health Care
- Exchange
- JL NYSE
- BCDA Nasdaq
- Market Cap
- JL 10.0M
- BCDA 11.0M
- IPO Year
- JL 2024
- BCDA N/A
- Fundamental
- Price
- JL $6.04
- BCDA $2.15
- Analyst Decision
- JL
- BCDA Strong Buy
- Analyst Count
- JL 0
- BCDA 1
- Target Price
- JL N/A
- BCDA $25.00
- AVG Volume (30 Days)
- JL 18.4K
- BCDA 52.3K
- Earning Date
- JL 07-07-2025
- BCDA 08-12-2025
- Dividend Yield
- JL N/A
- BCDA N/A
- EPS Growth
- JL N/A
- BCDA N/A
- EPS
- JL 0.54
- BCDA N/A
- Revenue
- JL $32,831,195.00
- BCDA $3,000.00
- Revenue This Year
- JL N/A
- BCDA N/A
- Revenue Next Year
- JL N/A
- BCDA N/A
- P/E Ratio
- JL $11.29
- BCDA N/A
- Revenue Growth
- JL 7.72
- BCDA N/A
- 52 Week Low
- JL $2.33
- BCDA $1.63
- 52 Week High
- JL $13.41
- BCDA $4.66
- Technical
- Relative Strength Index (RSI)
- JL 66.11
- BCDA 51.13
- Support Level
- JL $5.63
- BCDA $1.98
- Resistance Level
- JL $6.43
- BCDA $2.45
- Average True Range (ATR)
- JL 0.41
- BCDA 0.17
- MACD
- JL -0.04
- BCDA 0.01
- Stochastic Oscillator
- JL 71.08
- BCDA 53.19
About JL J-LONG GROUP LIMITED
J-Long Group Ltd is an established distributor in Hong Kong of reflective and non-reflective garment trims including, among others, heat transfers, fabrics, woven labels and tapes, sewing badges, piping, zipper pullers and drawcords. It also offers a wide range of apparel solution services to cater to its customers' needs for reflective and non-reflective garment trims, ranging from market trend analysis, product design and development and production to quality control.
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).